Market Closed -
Other stock markets
|
After market 16:00:01 | |||
79.54 EUR | +1.83% | 79.19 | -0.44% |
05-07 | Barclays Adjusts Edwards Lifesciences Price Target to $101 From $100 | MT |
05-01 | Edwards Lifesciences Insider Sold Shares Worth $1,212,687, According to a Recent SEC Filing | MT |
Evolution of the average Target Price on Edwards Lifesciences Corporation
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Edwards Lifesciences Corporation
Barclays | |
Bernstein | |
Evercore ISI | |
Stifel Nicolaus | |
Wells Fargo Securities | |
UBS | |
Piper Sandler | |
Canaccord Genuity | |
Baird | |
Leerink Partners | |
Zacks Investment Research | |
Truist Securities | |
RBC Capital Markets | |
Mizuho Securities | |
Citigroup | |
Morgan Stanley | |
Oppenheimer | |
BofA Securities | |
Jefferies & Co. | |
JPMorgan Chase | |
Wolfe Research | |
Deutsche Bank Securities | |
TD Cowen | |
Raymond James | |
Goldman Sachs | |
Cowen | |
SVB Leerink | |
Credit Suisse | |
Atlantic Equities |
EPS Revisions
- Stock Market
- Equities
- EW Stock
- EWL Stock
- Consensus Edwards Lifesciences Corporation